Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid

Clinical Cancer Research

Volumn 8, Issue 12, 2002, Pages 3747-3754

  Van Hensbergen, Yvette ^a   Broxterman, Henk J ^a   Hanemaaijer, Roeland ^b   Jorna, Anita S ^a   Van Lent, Natascha A ^b   Verheul, Henk M W ^a   Pinedo, Herbert M ^a   Hoekman, Klaas ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; ENDOSTATIN; GELATINASE A; GELATINASE B; ISOENZYME; MICROSOMAL AMINOPEPTIDASE; PLASMIN; UROKINASE; VASCULOTROPIN;

ADULT; ANGIOGENESIS; ARTICLE; CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; EFFUSION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTIGENS, CD13; ASCITIC FLUID; COLLAGEN; ENDOSTATINS; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOBLOTTING; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASMS; PEPTIDE FRAGMENTS; PLASMIN; PLEURAL EFFUSION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036899698     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Look, A. T., Ashmun, R. A., Shapiro, L. H., and Peiper, S. C. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J. Clin. Investig., 83: 1299-1307, 1989.
2. Dixon, J., Kaklamanis, L., Turley, H., Hickson, I. D., Leek, R. D., Harris, A. L., and Gatter, K. C. Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J. Clin. Pathol., 47: 43-47, 1994.
3. Saiki, I., Fuji, H., Yoneda, J., Abe, F., Nakajima, M., Tsuruo, T., and Azuma, I. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int. J. Cancer, 54: 137-143, 1993.
4. Pasqualini, R., Koivunen, E., Kain. R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R. A., Shapiro, L. H., Arap, W., and Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 60: 722-727, 2000.
5. Bhagwat, S. V., Lahdenranta, J., Giordano, R., Arap, W., Pasqualini, R., and Shapiro, L. H. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood, 97: 652-659, 2001.
6. Fenton, K. N., and Richardson, J. D. Diagnosis and management of malignant pleural effusions. Am. J. Surg., 170: 69-74, 1995.
7. Sahn, S. A. Pleural diseases related to metastatic malignancies. Eur. Respir. J., 10: 1907-1913, 1997.
8. Ferrara, N., and Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev., 18: 4-25, 1997.
9. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular permeability and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.
10. Zebrowski, B. K., Yano, S., Liu, W., Shaheen, R. M., Hicklin, D. J., Putnam, J. B., Jr., and Ellis, L. M. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res., 5: 3364-3368, 1999.
11. Verheul, H. M., Hoekman, K., Lupu, F., Broxterman, H. J., van der Valk, P., Kakkar, A. K., and Pinedo, H. M. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin. Cancer Res., 6: 166-171, 2000.
12. Zebrowski, B. K., Liu, W., Ramires, K., Akagi, Y., Mills, G. B., and Ellis, L. M. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol., 6: 373-378, 1999.
13. Thickett, D. R., Armstrong, L., and Millar, A. B. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax, 54: 707-710, 1999.
14. Cheng, D., Rodriguez, R. M., Perkett, E. A., Rogers, J., Bienvenu, G., Lappalainen, U., and Light, R. W. Vascular endothelial growth factor in pleural fluid. Chest, 116: 760-765, 1999.
15. Hazelton, D., Nicosia. R. F., and Nicosia, S. V. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin. Cancer Res., 5: 823-829, 1999.
16. Eickelberg, O., Sommerfeld, C. O., Wyser, C., Tamm, M., Reichenberger, F., Bardin, P. G., Solèr, M., Roth, M., and Perruchoud, A. P. MMP and TIMP expression pattern in pleural effusions of different origins. Am. J. Resp. Crit. Care Med., 156: 1987-1992, 1997.
17. Paju, A., Sorsa, T., Tervahartiala, T., Koivunen, E., Haglund, C., Leminen, A., Wahlström, T., Salo, T., and Stenman, U-H. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not with promatrix metalloproteinase-2 activation. Br. J. Cancer, 84: 1363-1371, 2001.
18. Hurewitz, A. M., Zucker, S., Mancuso, P., Wu, C. L., Dimassimo, B., Lysik, R. M., and Moutsiakis, D. Human pleural effusions are rich in metalloproteinases. Chest, 102: 1808-1814, 1992.
19. Furuya, M., Ishikura, H., Kawarada, Y., Ogawa, Y., Sakuragi, N., Fujimoto, S., and Yoshiki, T. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms. Gynecol. Oncol., 78: 106-112, 2000.
20. Macaulay, V. M., O'Byrne, K. J., Saunders, M. P., Braybrooke, J. P., Long, L., Gleeson, F., Mason, C. S., Harris, A. L., Brown, P., and Talbot, D. C. Phase I study of intrapleural Batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin. Cancer Res., 5: 513-520, 1999.
21. Kuhn, W., Schmalfeldt, B., Reuning, U., Pache, L., Berger, U., Ulm, K., Harbeck, N., Späthe, K., Dettmar, P., Höfler, H., Jänicke, F., Schmitt, M., and Graeff, H. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br. J. Cancer, 79: 1746-1751, 1999.
22. Favaloro, E. J., Browning, T., and Nandurkar, H. The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isoform of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150. Clin. Chim. Acta, 220: 81-90, 1993.
23. Favaloro, E. J., Browning, T., and Facey, D. CD13(GPI50: Aminopeptidase-N): Predominant functional activity in blood is localized to plasma and is not cell-surface associated. Exp. Hematol., 21: 1695-1701, 1993.
24. Freitas, I., Baronzio, G. F., Bono, B., Griffini, P., Bertone, V., Sonzini, N., Magrassi, G. R., Bonandrini, L., and Gerzeli, G. Tumor interstitial fluid: Misconsidered component of the internal milieu of a solid tumor. Anticancer Res., 17: 165-172, 1997.
25. Favaloro, E. J. CD-13 (gp150, aminopeptidase N): Co-expression on endothelial and hematopoietec cells with conservation of functional activity. Immunol. Cell. Biol., 69: 253-260, 1991.
26. Capper, S. J., Verheijen, J., Smith, L., Sully, M., Visser, H., and Hanemaaijer, R. Determination of Gelatinase-A (MMP-2) activity using a novel immunocapture assay. Ann. N. Y. Acad. Sci., 878: 487-490. 1999.
27. Hanemaaijer, R., Visser, H., Konttinen, Y. T., Koolwijk, P., and Verheijen, J. H. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: Saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol., 17: 657-665, 1998.
28. Gveric, D., Hanemaaijer, R., Newcombe, J., van Lent, N. A., Sier, C. F., and Cuzner, M. L. Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage. Brain, 124: 1978-1988, 2001.
29. Koolwijk, P., van Erck, M. G., de Vree, W. J., Vermeer, M. A., Weich, H. A., Hanemaaijer, R., and van Hinsbergh, V. W. Cooperative effect of TNF-α, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J. Cell. Biol., 132: 1177-1188, 1996.
30. O'Connell, P. J., Gerkis, V., and d'Apice. A. J. Variable O-glycosylation of CD13 (aminopeptidase N). J. Biol. Chem., 266: 4593-4597, 1991.
31. Fujii, H., Nakajima, M., Saiki, I., Yoneda, J., Azuma, I., and Tsuruo, T. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin. Exp. Metastasis, 13: 337-344, 1995.
32. Ehlers, M. R., and Riordan, J. F. Membrane proteins with soluble counterparts: Role of proteolysis in the release of transmembrane proteins. Biochemistry, 30: 10065-10074, 1991.
33. Braybrooke, J. P., O'Byrne, K. J., Propper, D. J., Blann, A., Saunders, M., Dobbs, N., Han, C., Woodhull, J., Mitchell, K., Crew, J., Smith, K., Stephens, R., Ganesan, T. S., Talbot, D. C., and Harris, A. L. A Phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin. Cancer Res., 6: 4697-4704, 2000.
34. Wajih, N., Walter, J., and Sane, D. C. Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor (c-met). Circ. Res., 90: 46-52, 2002.
35. Kraft, A., Weindel, K., Ochs, A., Marth, C., Zmija, J., Schumacher, P., Unger, C., Marme, D., and Gastl, G. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (Phila.), 85: 178-187, 1999.
36. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., and Jain, R. K. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res., 55: 3752-3756, 1995.
37. Krol, A., Maresca, J., Dewhirst, M. W., and Yuan, F. Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: Implications for drug delivery. Cancer Res., 59: 4136-4141, 1999.
38. Monsky, W. L., Fukumura, D., Gohongi, T., Ancukiewcz, M., Weich, H. A. Torchilin V. P., Yuan F., and Jain R. K. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res., 59: 4129-4135, 1999.
39. Feldman, A. L., Tamarkin, L., Paciotti, G. F., Simpson, B. W., Linehah, W. M., Yang, J. C., Fogler, W. E., Turner, E. M., Alexander, H. R., Jr., and Libutti, S. K. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin. Cancer Res., 6: 4628-4634, 2000.
40. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.